Millennium Pharmaceuticals Limited

The General Hospital Corporation

Massachusetts General Hospital Corporation

Stephen J Blakemore

Peter G Smith

George J Mulligan

Matthew C Schu

Bin Li

Jeffrey E Settleman

Eric S Lightcap

William L Trepicchio

Cyril H Benes

Jonathan L Blank

Hyunjin Shin

Alessandra M Di Bacco

Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Biomarkers of response to NAE inhibitors

Disclosed herein are markers associated with sensitivity to treatment with therapeutic agents. Methods to identify markers for predicting outcome to treatment with a therapeutic agent are disclosed as well as methods to predict outcome of treatment using markers. Compositions and methods are provided to predict response to NAE inhibition or EGFR inhibition treatment.

Biomarkers and methods to predict response to inhibitors and uses thereof

Growing community of inventors

Littleton, MA, United States of America

Stephen J Blakemore